Christopher J. Schaber, Ph.D, president and CEO of Soligenix Inc. SNGX, was lately a visitor on Benzinga’s All-Entry.
Soligenix, a late-stage biopharmaceutical firm, is targeted on growing and commercializing remedies for uncommon illnesses. The corporate’s key focus is on HyBryte™, a novel photodynamic remedy for cutaneous T-cell lymphoma, and the enlargement of artificial hypericin into psoriasis and different inflammatory illnesses.
Schaber shared thrilling updates from the corporate’s section 3 examine of HyBryte. Preliminary outcomes are anticipated in mid 2026.
Watch the complete interview right here:
Featured photograph by Online Marketing on Unsplash.
This publish comprises sponsored content material. This content material is for informational functions solely and isn’t supposed to be investing recommendation.
Market Information and Knowledge dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
